In short
Pharmaniaga Berhad (7081.KL) has revenue up 4.5% to MYR 3.9B and net income down 63.2% to MYR 48.5M year on year. Its net margin is 1.2% and gross margin 10.4%, and it trades at 6.3× trailing earnings. Fisclear flags 1 high-severity risk, led by: Current ratio of 0.91x — short-term liabilities exceed current assets, which could create near-term liquidity pressure. How we calculate this
Valuation
HealthcareLive · Yahoo FinancePrice
RM0.78
RM1.0B
11.5x
2.23%
52-Week Range
4-engine score — Quality and Peers engines require SEC EDGAR (US stocks only)
P/E 6.5× — low multiple.
Based on filing period ending Dec 2025
International FisclearScore uses 4 engines (no EDGAR data). Based on Yahoo Finance & Alpha Vantage reported financials. Not financial advice.
🇲🇾 Malaysia Macro Indicators
Full dashboard →Policy Rate
2.75%→
Moderate
CPI Inflation
1.80%→
Near target · +0.10% MoM
Unemployment
2.90%↓
Tight labour market
GDP Growth
6.00%↑
Strong
USD/MYR
4.08→
Current Account
1.61% GDP↑
Surplus
The Malaysia central bank policy rate stands at 2.75% — a moderately elevated rate environment; CPI inflation is 1.8% year-over-year (inflation near target); unemployment stands at 2.9% (tight labour market); GDP growth is 6.0% year-over-year (strong growth); USD/MYR is at 4.0843.
SWOT Analysis — 7081.KL
Inflationary BoomStrengths
Total Assets: MYR 2.2B (+12.8% YoY) — Total assets grew 13% — the company's resource base expanded.
Weaknesses
EPS (Diluted): MYR 0.07 (-75.4% YoY) — Earnings per share fell 75%.
Net Income: MYR 48.5M (-63.2% YoY) — Profit fell 63% but remained positive.
Gross Profit: MYR 409.2M (-24.3% YoY) — Gross profit declined 24% — costs are growing faster than revenue.
Gross margin narrowed by 4.0pp — worth monitoring for further cost pressure.
Opportunities
Revenue: MYR 3.9B (+4.5% YoY) — Revenue grew 4% — the company sold more goods or services than the prior year.
Threats
Current ratio of 0.91x — short-term liabilities exceed current assets, which could create near-term liquidity pressure.
Net income dropped 63% year-over-year — a significant compression in profitability.
Total liabilities represent 80% of total assets — elevated leverage that amplifies both gains and losses.
Stock is within 10% of its 52-week low (0.75) — the market may be pricing in significant risk or sector weakness.
Year-over-Year Changes
EPS (Diluted)
MYR 0.07
was MYR 0.27
Earnings per share fell 75%.
Net Income
MYR 48.5M
was MYR 131.8M
Profit fell 63% but remained positive.
Gross Profit
MYR 409.2M
was MYR 540.5M
Gross profit declined 24% — costs are growing faster than revenue.
Total Assets
MYR 2.2B
was MYR 2.0B
Total assets grew 13% — the company's resource base expanded.
Revenue
MYR 3.9B
was MYR 3.8B
Revenue grew 4% — the company sold more goods or services than the prior year.
Risk Flags
1 high · 3 medium · 1 low- ⚠ High
Current ratio of 0.91x — short-term liabilities exceed current assets, which could create near-term liquidity pressure.
- ◈ Medium
Net income dropped 63% year-over-year — a significant compression in profitability.
- ◈ Medium
Total liabilities represent 80% of total assets — elevated leverage that amplifies both gains and losses.
- ◈ Medium
Stock is within 10% of its 52-week low (0.75) — the market may be pricing in significant risk or sector weakness.
- ○ Low
Gross margin narrowed by 4.0pp — worth monitoring for further cost pressure.
Technical Signals
Daily closes · 1-year dataPharmaniaga Berhad: common questions
Is Pharmaniaga Berhad profitable?
Yes. Pharmaniaga Berhad made a net profit of RM49M in its latest fiscal year (fiscal 2025), a net margin of 1.2%.
Is Pharmaniaga Berhad's revenue growing?
Yes. Revenue grew 4.5% year on year, to MYR 3.9B.
What is Pharmaniaga Berhad's P/E ratio?
Pharmaniaga Berhad trades at 6.5× its trailing twelve-month earnings. In other words, the share price is about 6 times the profit per share the company earned over the past year.
Does Pharmaniaga Berhad pay a dividend?
Yes. Pharmaniaga Berhad's forward dividend yield is 2.23%, the expected annual dividend as a share of the current share price.
What are the main risks for Pharmaniaga Berhad?
Fisclear's checks flag 4 medium- or high-severity risks. The most serious: Current ratio of 0.91x — short-term liabilities exceed current assets, which could create near-term liquidity pressure.
Answers are generated from the figures in this report (updated 6 Nov 2026). Information, not investment advice.
Latest News
via FinnhubFiling History — 7081.KL
Get the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Research Pharmaniaga Berhad
Data sourced from Bursa Malaysia, FRED (Federal Reserve), OECD, BIS, and Yahoo Finance. For informational purposes only. Not financial advice.